Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Kerala Ayurveda
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 23.84 | 23.78 | 25.03 | 26.32 | 32.03 | 27.47 | 30.41 | 31.13 | 31.32 | 28.61 | 34.84 | 32.96 | 34.74 |
| Expenses + | 23.15 | 22.25 | 24.49 | 25.31 | 26.58 | 26.67 | 24.88 | 32.32 | 41.46 | 32.79 | 39.79 | 34.47 | 41.84 |
| Operating Profit | 0.69 | 1.53 | 0.54 | 1.01 | 5.45 | 0.80 | 5.53 | -1.19 | -10.14 | -4.18 | -4.95 | -1.51 | -7.10 |
| OPM % | 2.89% | 6.43% | 2.16% | 3.84% | 17.02% | 2.91% | 18.18% | -3.82% | -32.38% | -14.61% | -14.21% | -4.58% | -20.44% |
| Other Income + | 0.11 | 0.16 | 0.77 | 0.23 | -0.86 | 0.22 | 0.64 | 0.23 | 0.73 | 9.47 | 1.70 | 1.13 | 1.91 |
| Interest | 1.25 | 1.51 | 0.65 | 0.61 | 3.26 | 0.46 | 0.72 | 0.43 | 2.48 | 0.82 | 2.58 | 2.84 | 1.10 |
| Depreciation | 0.23 | 0.33 | 0.32 | 0.34 | 1.15 | 0.36 | 1.98 | 0.72 | 1.92 | 1.65 | 0.99 | 1.15 | 1.69 |
| Profit before tax | -0.68 | -0.15 | 0.34 | 0.29 | 0.18 | 0.20 | 3.47 | -2.11 | -13.81 | 2.82 | -6.82 | -4.37 | -7.98 |
| Tax % | -170.59% | 106.67% | 100.00% | 368.97% | -194.44% | -125.00% | -4.90% | 27.96% | 11.30% | 27.66% | -6.74% | 5.26% | -7.39% |
| Net Profit + | 0.47 | -0.30 | 0.00 | -0.79 | 0.53 | 0.46 | 3.65 | -2.70 | -15.38 | 2.03 | -6.36 | -4.60 | -7.39 |
| EPS in Rs | 0.17 | -0.34 | -0.12 | -0.90 | 0.22 | 0.27 | 2.84 | -2.40 | -12.92 | 1.65 | -5.26 | -3.69 | -5.97 |
Financials of Kerala Ayurveda
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 39 | 46 | 50 | 59 | 59 | 77 | 62 | 80 | 93 | 108 | 126 | 131 |
| Expenses + | 33 | 38 | 43 | 51 | 54 | 69 | 61 | 71 | 91 | 100 | 131 | 149 |
| Operating Profit | 6 | 8 | 7 | 8 | 5 | 7 | 1 | 10 | 3 | 9 | -5 | -18 |
| OPM % | 15% | 16% | 14% | 14% | 9% | 10% | 1% | 12% | 3% | 8% | -4% | -14% |
| Other Income + | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 3 | 0 | 2 | 14 |
| Interest | 2 | 2 | 1 | 2 | 3 | 2 | 6 | 7 | 5 | 6 | 4 | 7 |
| Depreciation | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 5 |
| Profit before tax | 3 | 4 | 4 | 4 | 3 | 5 | -7 | 3 | -1 | 1 | -12 | -16 |
| Tax % | 21% | 33% | 22% | 31% | 19% | 11% | -28% | 15% | -23% | 185% | 14% | -0% |
| Net Profit + | 3 | 3 | 3 | 3 | 3 | 4 | -5 | 2 | -0 | -1 | -14 | -16 |
| EPS in Rs | 2.24 | 2.56 | 2.90 | 2.66 | 2.31 | 3.69 | -4.59 | 2.24 | -0.85 | -0.47 | -11.60 | -12.74 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Kerala Ayurveda
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 12 | 12 | 13 |
| Reserves | -19 | -17 | -4 | -3 | -7 | -3 | -7 | -4 | -5 | 7 | -3 | -2 |
| Borrowings + | 70 | 69 | 56 | 75 | 62 | 64 | 77 | 70 | 72 | 76 | 71 | 86 |
| Other Liabilities + | 11 | 11 | 17 | 20 | 27 | 31 | 34 | 34 | 37 | 38 | 49 | 41 |
| Total Liabilities | 73 | 73 | 81 | 103 | 92 | 103 | 114 | 110 | 115 | 133 | 129 | 138 |
| Fixed Assets + | 33 | 34 | 34 | 32 | 33 | 33 | 33 | 44 | 46 | 41 | 47 | 50 |
| CWIP | 0 | 0 | 6 | 11 | 12 | 14 | 14 | 4 | 7 | 7 | 9 | 8 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 40 | 39 | 41 | 59 | 47 | 56 | 68 | 62 | 61 | 85 | 73 | 81 |
| Total Assets | 73 | 73 | 81 | 103 | 92 | 103 | 114 | 110 | 115 | 133 | 129 | 138 |
Financials of Kerala Ayurveda
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 0 | 6 | 4 | -10 | 12 | 5 | 7 | -0 | 10 | -1 | 5 | -24 |
| Cash from Investing Activity + | -0 | -3 | -3 | -3 | -3 | -4 | -1 | -2 | -7 | -0 | -15 | -5 |
| Cash from Financing Activity + | 2 | -2 | 0 | 17 | -12 | 1 | 6 | -13 | -1 | 20 | -9 | 32 |
| Net Cash Flow | 2 | -0 | 1 | 4 | -2 | 2 | 12 | -16 | 2 | 18 | -19 | 3 |
| Free Cash Flow | -0 | 2 | 3 | -16 | 10 | 2 | 6 | -3 | 4 | -2 | -8 | -30 |
| CFO/OP | 8% | 73% | 62% | -120% | 251% | 71% | 885% | -5% | 390% | 1% | -138% | 136% |
Financials of Kerala Ayurveda
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 35 | 33 | 35 | 34 | 43 | 51 | 61 | 61 | 51 | 59 | 56 | 38 |
| Inventory Days | 287 | 227 | 319 | 338 | 311 | 313 | 268 | 254 | 227 | 205 | 208 | 200 |
| Days Payable | 150 | 100 | 112 | 125 | 117 | 162 | 149 | 168 | 137 | 114 | 93 | 129 |
| Cash Conversion Cycle | 172 | 160 | 242 | 247 | 236 | 202 | 179 | 147 | 141 | 149 | 171 | 109 |
| Working Capital Days | -131 | -103 | -213 | -63 | -24 | -19 | -99 | -118 | -81 | -172 | -147 | -162 |
| ROCE % | 8% | 9% | 9% | 9% | 6% | 9% | -0% | 11% | 2% | 8% | -9% | -10% |
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…